Header Ads Widget

Responsive Advertisement

Ticker

6/recent/ticker-posts

Coronavirus Vaccine

 Experimental coronavirus vaccine highly effective

At a glance
Clinical trial results show that the investigative vaccine known as mRNA 1273 is 94.1% effective in preventing symptomatic CoVID-19.
These results indicate that the vaccine, now approved by the FDA for emergency use, is safe and effective.

Researchers are working to develop a safe and effective vaccine against SARS-CoV-2, the corona virus that causes COVID-19. A vaccine candidate, called mRNA-1273, developed by researchers at NIH's National Institute of Allergy and Infectious Diseases (NIAID) and the biotech company  showed preliminary results showing serious side effects. Can trigger an immune response against the virus. .

To further investigate the safety and efficacy of this vaccine, a research team led by Dr. Lindsay R.  of Boston's Brahms and Women's Hospital, Dr. Hannah ML Sahil of the Boiler College of Medicine, and Dr. Brandon Eisenhower. Meridian Clinical Research conducted clinical trials with more than 30,000 adult volunteers across the country. Participants were 18 years of age or older who did not have a previous SARS-Co-2 infection. The results were published in the New England Journal of Medicine on 30 December 2020.

Volunteers were randomly assigned to receive two doses of the investigative vaccine (100 micrograms each) or two shots of salted placebo. He received his first injection between July 27 and October 23, 2020. The second shot was fired 28 days later.

Investigators recorded 196 episodes of the symbolic COVID-19 between participants at least 14 days after their second shot. Only 11 of these cases were in the group that received the vaccine, and none of them are suspected. In contrast, there were 185 incidents in the placebo group, of which 30 were severe. Thus, the incidence of symptomatic CoVID-19 was 94.1% lower in participants who received mRNA-1273 than in placebo recipients. For participants 65 years of age or older, the utility was 86.4%.

There was no talk of immunizations. Local reactions to the vaccine were usually mild. After the second dose, approximately half of the NA participants experienced moderate to severe side effects such as fatigue, muscle aches, joint pain, and headaches. In most volunteers, this is resolved in two days.

One potential concern about the COVID-19 vaccine is an unusual phenomenon called vaccine-related respiratory disease or VAERD. VRD can occur when a vaccine triggers an immune response that causes the disease to become more serious if you are exposed to the virus. However, the team found no evidence of VAERD among the recipients of MRNA-1273.

"We still don't know about the Stork Cove 2 and Cove 19," he said. However, we do know that this vaccine is safe and that it can prevent symptomatic COVID-19 and serious illness, "said Dr. Anthony S.  director of NIAID. If available, they will protect themselves by vaccinating all Americans against polio. In the same way, our country will be healed and move forward.

The FDA issued an emergency use permit (link is external) on December 18, 2020 for the availability of a vaccine to prevent COVID-19 in adults.

Although mRNA-1273 can inhibit symptomatic CoVID-19, further studies are needed to determine whether it protects against SARS-CoV-2 transmission. Additional analyzes are also underway to understand the effects of the vaccine on asymptomatic infections.


Post a Comment

0 Comments